The Future of Health: Why Pharma and Life Sciences Leaders Are Rethinking Their Commercial Strategy
Healthcare is being rebuilt in real time. Patent cliffs are compressing revenue windows, patients are behaving more like consumers, and artificial intelligence is quietly becoming the interface between clinicians and clinical information. For pharmaceutical and life sciences executives, the question is no longer whether the industry will change — it's whether their organization is structured to keep pace with it. That question is exactly why healthcare consulting firms have moved from a peripheral resource to a core part of how leading companies plan their next five years. Why the Future of Health Is a Strategic Question, Not Just a Clinical One It's tempting to think of the future of health as a story about science — new modalities, faster trials, better diagnostics. That's part of it, but the bigger shift is commercial and operational. Manufacturers are being asked to prove value, not just efficacy, to a widening circle of payers, providers, and increasingly price-sens...